ClinicalTrials.gg
CompletedNCT04622553Updated Sep 8, 2026

Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

An interventional study of Mexiletine in Myotonic Disorders, sponsored by Lupin Ltd.. Completed at 1 site in France. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Lupin Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Study summary

Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed the MEX-NM-301 study.

Read the detailed description

This is an open-label extension study evaluating the long-term efficacy and safety of mexiletine in paediatric patients with myotonic disorders who have completed the initial parent paediatric study with mexiletine (Protocol No. MEX-NM-301 (PIP Study 4) for children and adolescents aged 6 to \< 18 years and who continue to meet the eligibility criteria.

Patients who meet the eligibility criteria and provide consent for this study will be enrolled sequentially by decreasing age groups. Patients aged 12 to \< 18 years will enter first as this is the first cohort expected to complete the parent study PIP Study 4 based on top down recruiting. Once initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, patients aged 6 to \<12 years will be first enrolled in PIP Study 4 and subsequently this study (PIP Study 7).

Enrolled patients will receive mexiletine at a dose determined in the parent study. Dosing is determined according to body weight and tolerability.

The study includes 9 clinic visits - V1 (baseline), and V2 to V9 every 3 months, approximately, thereafter.

The total duration of study will be 24 months per patient. End-of-treatment (EOT) visit will occur at 24 months or in accordance with the availability of product. The overall study duration would be approximately 5 years.

02

Conditions studied

  • Myotonic Disorders
03

In context

Lead sponsor

Lupin Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients previously completed the parent study PIP study 4 (MEX-NM-301) and tolerated the Mexiletine in the study.
  2. Able and willing to provide assent to study participation and a parent or legal guardian willing to sign written prior to study entry.
  3. Patients continue to meet inclusion criteria of parent study (MEX-NM-301):

    • No significant cardiac abnormalities as determined by a cardiologist's assessment of the and Echocardiogram
    • No history or evidence of any significant liver disorder Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within normal range, or showing no abnormal values, as judged by the Investigator
    • Female patients of must be using an acceptable form of as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or have a vasectomized partner or are practicing abstinence

Exclusion criteria

Exclusion Criteria:

  1. laboratory abnormality, or other clinical findings on physical examination indicative of a clinically significant exclusionary disease as determined by the investigator
  2. Any to mexiletine (as described in the Namuscla Summary of Product Characteristics [SmPC])

    • to the active substance, or to any of the
    • Hypersensitivity to any local anaesthetic
    • Ventricular tachyarrhythmia
    • Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
    • > 450ms
    • Myocardial infarction (acute or past), or abnormal Q-waves
    • Symptomatic coronary artery disease
    • Heart failure with \<50%
    • Atrial tachyarrhythmia, fibrillation or flutter
    • Sinus node dysfunction (including sinus rate \< 50 bpm)
    • Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
    • Co-administration with medicinal products with narrow therapeutic index
  3. Co- administration with antiarrhythmics
  4. Any other neurological or psychiatric condition that might affect the assessment of the study measurements
  5. Any concurrent illness, or medications which could affect the muscle function
  6. Seizure disorder, diabetes mellitus requiring treatment by insulin
  7. Pregnant or breastfeeding
  8. Concurrent participation in any other clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    Cohort 1 and 2

    7 patients aged 12 to \< 18 years , inclusive in cohort-1 7 patients aged 6 to \< 12 years, inclusive in cohort-2

    Drug: Mexiletine

Interventions

  • Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Cohort 2- (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1

    Also known as: Namuscla ™

06

What researchers measure

Primary outcomes

  1. Assess the long-term safety and tolerability of mexiletine by AEs

    Assess the long-term safety and tolerability of mexiletine in paediatric patients by number and frequency of AEs/SAEs, throughout the study while on treatment

    Time frame: Approximately 24 months

  2. Assess the long-term safety and tolerability of mexiletine by hand relaxation

    Mean time (in seconds) to relaxation of hand muscles and reduction in relaxation time from the first to the fifth contraction

    Time frame: Approximately 24 months

  3. Assess the long-term safety and tolerability of mexiletine measurement of AESI

    Assess the long-term safety and tolerability of mexiletine in paediatric patients by Incidence of adverse events of special interest (AESI),

    Time frame: Approximately 24 months

  4. Assess the long-term safety and tolerability of mexiletine by changes in ECG

    Assess the long-term safety and tolerability of mexiletine in paediatric patients by changes in ECG assessments from baseline, repeated at each study visit

    Time frame: Approximately 24 months

  5. Assess the long-term safety and tolerability of mexiletine by muscle stiffness

    Score for muscle stiffness (myotonia severity) as self-reported by the patients on a Visual Analog Scale (VAS) or Faces scale

    Time frame: Approximately 24 months

Secondary outcomes

  1. Mean change in VAS

    Mean change in VAS (8 to \< 18 years) or Faces (6 to \< 8 years) score for severity of muscle stiffness (if not a primary endpoint) pain, weakness and fatigue (every 3 months).

    Time frame: Approximately 24 months

  2. Clinical myotonia assessment

    Mean change in time to open the eyes after forced eye closure as measured on a stopwatch (when eyelid myotonia present)

    Time frame: Approximately 24 months

  3. Mean change in health-related quality-of-life

    Mean change in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score (secondary endpoint for patients aged 6 years to \<18 years; every 6 months).

    Time frame: Approximately 24 months

  4. Clinical Global Impression (CGI) scores

    Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient, a parent or proxy and by the investigator. Measured every 6 months

    Time frame: Approximately 24 months

  5. Mean change in Myotonia Behaviour Scale (MBS) scores

    Mean change in Myotonia Behaviour Scale (MBS) scores (for patients aged 6 years to \< 18 years; measured every 6 months).

    Time frame: Approximately 24 months

  6. Mean change in time to perform Timed-up and go (TUG) test

    Mean change in time to perform Timed-up and go (TUG) test (patients aged 6 to \<18 years only)

    Time frame: Approximately 24 months

07

Study locations

1 site
  • Hôpital Necker-Enfants-Malades
    Paris, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jun 2026, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2020
First posted
Nov 10, 2020
StartActual
Nov 5, 2021
Primary completionActual
Jun 4, 2026
CompletionActual
Jun 4, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04622553
Lead sponsor
Lupin Ltd.
Responsible party
Sponsor
First posted
Nov 10, 2020
Start date
Nov 5, 2021
Primary completion
Jun 4, 2026
Completion
Jun 4, 2026
Last update
Sep 8, 2026

Study contacts

Christine Barnérias, MD
principal investigator · Hopital universitaire Necker-Enfants Malades

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mexiletine

Start the discussion